CLIPPERS: INDUCTION AND MAINTENANCE OF REMISSION USING HYDROXYCHLOROQUINE

OPEN

Chronic lymphocytic inflammation and pontine perivascular enhancement responsive to steroids (CLIPPERS) is a condition that was first described by Pittock et al. in 2010 and is characterized by brainstem symptoms, gait ataxia, and diplopia. Brain MRIs of patients demonstrate punctate or nodular gadolinium-enhancing lesions in the pons. CLIPPERS is a diagnosis of exclusion through laboratory, radiologic, or histologic tests. Most patients to date have been treated with steroids, with some eventually switching to other immunosuppressants with variable and significant side effect profiles. We describe a patient with CLIPPERS in whom treatment with hydroxychloroquine was successful in inducing and maintaining the remission of symptoms confirmed by radiologic resolution.

Classification of evidence. This article provides Class IV evidence. It is a single observational study without controls.

Case presentation. A 54-year-old man presented in 2009 with a 12-month history of intermittent bilateral motor and sensory symptoms eventually progressing to blurred vision. Examination revealed square wave jerks and saccadic intrusion of pursuit movements, gait ataxia, and bilateral trigeminal sensory involvement. Serial postcontrast T1-weighted MRI sequences revealed multiple progressive punctiform white matter lesions involving the pons and cerebellar peduncles bilaterally (figure). Laboratory tests including full blood count, liver function, renal function, autoimmune screens, paraneoplastic antibodies, vitamin levels, and inflammatory markers were normal. CSF showed a mildly elevated protein of 0.44 g/L (normal range 0.1–0.4 g/L), unremarkable cell count (4 red cells/μL, 3 lymphocytes/μL), and an elevation in unmatched oligoclonal bands. Treatment with glatiramer acetate was started in April 2010 for a presumptive diagnosis of multiple sclerosis. After further neuroradiologic review, multiple sclerosis was considered unlikely and the possibility of neurosarcoïdosis was considered, although serum angiotensin-converting enzyme and chest x-ray were normal. Glatiramer acetate was stopped within 6 weeks of initiation, and treatment with hydroxychloroquine 200 mg twice daily was started in May 2010. This was followed by significant and prompt resolution of symptoms and improved imaging. With the lack of peripheral and laboratory features of sarcoidosis and eventual recognition that the MRI brain findings were similar to those recently reported in the literature, the diagnosis was changed to CLIPPERS in 2011. He was diagnosed with Dukes’ C colon cancer and underwent a hemicolectomy and 12 cycles of chemotherapy at the end of 2012. His hydroxychloroquine was put on hold for a month while he received the chemotherapy but was resumed after completion of the cancer treatment. At follow-up 4 years later, there is no evidence of residual malignancy. There has been no recurrence of neurologic symptoms and complete resolution of the MRI changes (figure) on maintenance hydroxychloroquine.

Discussion. CLIPPERS is a relapsing-remitting condition and long-term sequelae are dependent on the severity of relapses. The pathogenesis of CLIPPERS eludes the scientific community, and our understanding of this condition is still in its infancy. Reports have suggested that it could be part of a subset of multiple sclerosis or could overlap with primary CNS angitis, with a possible link to fatal B-cell lymphoma. The current proposal that CLIPPERS is an immune-mediated condition is based on T-cell–predominant infiltrates in affected lesions and resolution of these lesions radiographically with immunosuppression.

Hydroxychloroquine was initially used as an antimalarial drug and subsequently as an immunomodulator in the treatment of rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. Fox et al. proposed its action as an immunomodulator in 1996, suggesting that it may have an effect on macrophages. However, the mechanism of action of hydroxychloroquine has not been replicated and validated since this proposal and remains uncertain. Hydroxychloroquine was used in a patient with CLIPPERS described by Pittock et al., but it was withdrawn due to radiologic progression despite maintenance of clinical remission. Since then, hydroxychloroquine has not been used in subsequent cases.
cases. Although hydroxychloroquine was originally initiated to treat presumed sarcoidosis, induction of remission was achieved within 2 weeks of commencement of treatment in this patient with CLIPPERS. The lesions on imaging resolved concurrently with his clinical improvement and he remains symptom-free to date. The initial brief exposure to glatiramer acetate would not account for the sustained remission seen. The clinical and radiologic recovery more than 2 years prior to recognition and successful treatment of his malignancy is inconsistent with his presentation being due to paraneoplastic syndrome. To the best of our knowledge, this is the first case of CLIPPERS successfully treated and maintained with hydroxychloroquine. Hydroxychloroquine is a relatively inexpensive option that is generally well-tolerated with a favorable side effect profile compared to other immunosuppressive therapies. We believe it should be considered as an alternative in the treatment of CLIPPERS.

From Clovelly Park (B.L.T.), South Australia; and Department of Medical Imaging (M.A.) and Department of Neurology (D.W.S.), Flinders Medical Centre, Bedford Park, Australia.

Author contributions: Dr. Boon Loong Tan: acquisition of data, drafting/revising the manuscript for content, including medical writing for content. Dr. Marc Agzarian: drafting/selecting/formatting image, title, and legend. Dr. David W. Schultz: acquisition of data, revising the manuscript for content, including medical writing for content, case supervisor.

Study funding: No targeted funding reported.

Disclosure: The authors report no disclosures. Go to Neurology.org/nn for full disclosures. The Article Processing Charge was paid by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received August 20, 2014. Accepted in final form October 28, 2014.

Correspondence to Dr. Tan: bltan1982@hotmail.com


5. De Graaff HJ, Vattjes MP, Rozemuller-Kwakkel AJ, Petzold A, Killestein J. Fatal B-cell lymphoma following...
chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. JAMA Neurol 2013;70:915–918.
**CLIPPERS: Induction and maintenance of remission using hydroxychloroquine**

Boon Loong Tan, Marc Agzarian and David W. Schultz

*Neurol Neuroimmunol Neuroinflamm* 2015;2; DOI 10.1212/NXI.0000000000000056

This information is current as of January 14, 2015

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/2/1/e56.full.html">http://nn.neurology.org/content/2/1/e56.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 7 articles, 1 of which you can access for free at: <a href="http://nn.neurology.org/content/2/1/e56.full.html##ref-list-1">http://nn.neurology.org/content/2/1/e56.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): Autoimmune diseases <a href="http://nn.neurology.org//cgi/collection/autoimmune_diseases">http://nn.neurology.org//cgi/collection/autoimmune_diseases</a> Class IV <a href="http://nn.neurology.org//cgi/collection/class_iv">http://nn.neurology.org//cgi/collection/class_iv</a> Gait disorders/ataxia <a href="http://nn.neurology.org//cgi/collection/gait_disorders_ataxia">http://nn.neurology.org//cgi/collection/gait_disorders_ataxia</a> MRI <a href="http://nn.neurology.org//cgi/collection/mri">http://nn.neurology.org//cgi/collection/mri</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: <a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>

*Neurol Neuroimmunol Neuroinflamm* is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2015 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.